Please register to participate in our discussions with 2 million other members - it's free and quick! Some forums can only be seen by registered members. After you create your account, you'll be able to customize options and access all our 15,000 new posts/day with fewer ads.
Tests don't have a fixed false positive or false negative rate. Those depend on the sensitivity and specificity of the test and the prevalence of what you're testing for in the population you are testing. What is fixed is a test's sensitivity and specificity. Running exactly the same test in two populations with a very different incidence of whatever it is you are testing for can give very different false positive and false negative rates. https://en.wikipedia.org/wiki/Positi...dictive_values
The Abbot test currently has a claimed sensitivity of 100% and specificity of 99.5% (https://www.evaluate.com/vantage/art...ecific-problem). I expect both numbers to go down slightly as most data comes in, as these tests haven't been as thoroughly researched as most new tests are before being brought to market. (In particular, no test is ever 100% sensitive or specific, though greater than 99.5 percent is what most good tests aim for - the higher, the better.)
One should be able to determine the False Positive and False Negative rates from specificity and sensitivity numbers.
If SP, SN and Testing Sample Size are known, then we have 3 equations and 4 unknowns. I am missing one equation here to get to the TN, TP, FN, FP numbers. I am sure they have it for calculating the SP and ST. Hopefully someone can spot what I am missing...
People in NY probably have better access to health care than most. Like you, I'm skeptical that they could be more healthy though. They could well have a higher preponderance of people with existing medical conditions, since they are more likely to be rescued from death.
NY has significantly lower obesity rates.
I dont think people in West Virginia would have the same death rate as people in NY from this virus.
One should be able to determine the False Positive and False Negative rates from specificity and sensitivity numbers.
No, they vary with the prevalence of the condition in the population. You have to do a Bayesian analysis to calculate the false positive and false negative rates for a population for which the analyte you're testing for is present at X% of the population. Look at the Wikipedia link I posted (here) to see the actual calculations and some worked examples (using the fecal occult blood test as a screening tool for colon cancer).
These Treatment Guidelines have been developed to inform clinicians how to care for patients with COVID-19. Because clinical information about the optimal management of COVID-19 is evolving quickly, these Guidelines will be updated frequently as published data and other authoritative information becomes available.
If there was only a way to bet against these companies long-term. The majority of drug trials flame out. I would end up losing my shirt, if they stocks keep rising short term.
A very interesting idea -the therapeutic application of molecular hydrogen gas. This adaptive anti-oxidant has great potential in reducing/controlling hyperinflammation. It is produced by a molecular hydrogen gas generator and can be administered via a nasal cunnula. Inexpensive, non-invasive and with high safety profile.
I live just across the river in NJ, and knew it was bad over there - but not that bad.
(not that NJ is much better)
Please register to post and access all features of our very popular forum. It is free and quick. Over $68,000 in prizes has already been given out to active posters on our forum. Additional giveaways are planned.
Detailed information about all U.S. cities, counties, and zip codes on our site: City-data.com.
Please register to participate in our discussions with 2 million other members - it's free and quick! Some forums can only be seen by registered members. After you create your account, you'll be able to customize options and access all our 15,000 new posts/day with fewer ads.
NIH Panel Develops COVID-19 Treatment Guidelines
